News & Updates
Filter by Specialty:
NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes
Women with nonalcoholic fatty liver disease (NAFLD), despite having a normal weight, remains at greater risk of adverse pregnancy outcomes, reveals a study.
NAFLD, regardless of obesity status, ups risk of adverse pregnancy outcomes
26 Jan 2023
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
20 Jan 2023
G-CSF primary prophylaxis reduces febrile neutropenia and hospitalization, maintains chemo dose in early BC
Using a 4-day, fixed-dose schedule of filgrastim as granulocyte-colony stimulating factor (G-CSF) primary prophylaxis reduces the incidence of febrile neutropenia (FN) and associated hospitalization while maintaining the doses of adjuvant docetaxel and cyclophosphamide (TC) among Chinese women with early breast cancer (BC), a retrospective cohort study in Hong Kong has shown.